

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. *N Engl J Med* 2005;353:123-32.

Supplementary Table 1

A comparison of time to deterioration of lung cancer related symptoms

	Erlotinib		Placebo		P Value*
	Number	Median (95% CI)	Number	Median (95% CI)	
Cough	298	4.9 mos (3.8-7.4 mos)	153	3.7 mos (2.0-4.9 mos)	0.04
Dyspnea	253	4.7 mos (3.8-6.2 mos)	179	2.9 mos (2.0-4.8 mos)	0.03
Pain	348	2.8 mos (2.4-3.0 mos)	179	1.9 mos (1.8-2.8 mos)	0.04

* Hochberg adjusted p value

Supplementary Table 2

A comparison of quality of life scores

	Erlotinib			Placebo			P Value
	Improve	Stable	Worsen	Improve	Stable	Worsen	Chi
Disease							
Pain	42	15	43	28	20	51	0.01
Dyspnea	34	27	40	23	33	44	0.03
Cough	44	24	32	27	31	41	0.00
Fatigue	45	4	51	36	8	55	0.06
Overall							
Physical	31	18	51	19	24	57	0.01
Emotional	39	24	37	30	36	35	0.01
Global	35	16	49	26	28	46	0.00